111, Inc. YI
Retail-Drug Stores and Proprietary Stores · IPO 2018 · data as of November 13, 2026
111, Inc. (YI) is a consumer staples company listed in the US with a market value of about $25M. In fiscal year 2025 it had revenue of $1.8B and net income of -$9M, a net margin of -0.5%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (3/5); the weakest is track record (0/5).
Key numbers: a price to free cash flow of 1.5, 5-year revenue growth of 7% a year, a 5-year average ROIC of -202%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 1511% above the current price.
About 111
111 is listed in the US and classified in retail-drug stores and proprietary stores, IPO year 2018. Revenue went from $260M in 2018 to $1.8B in 2025, growth of about 31.8% a year. It was profitable in 0 of the last 10 years in our data.
Score: 1.4 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.8B | $2.0B | $2.1B | $2.0B | $1.9B | $1.3B | $568M | $260M | — | — |
| Net income | -$9M | -$9M | -$55M | -$60M | -$105M | -$70M | -$72M | -$56M | -$38M | -$52M |
| Free cash flow | $16M | $34M | -$64M | -$8M | -$118M | -$22M | -$76M | -$52M | — | — |
| EPS (diluted) | $-1.08 | $-1.01 | $-6.29 | $-6.87 | $-11.95 | $-7.95 | $-8.16 | $-6.31 | $-4.36 | $-5.95 |
| Net margin | -0.5% | -0.4% | -2.6% | -3.1% | -5.4% | -5.6% | -12.6% | -21.4% | — | — |
| ROIC | — | — | — | — | -201.7% | -54.5% | -40.6% | -24.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is 111 stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 1511% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does 111 pay a dividend?
Not currently.
Is 111 a good stock to buy?
We do not give buy or sell advice. 111 scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.